ஜர்னல் ஆஃப் புரோட்டியோமிக்ஸ் & பயோ இன்ஃபர்மேடிக்ஸ்
திறந்த அணுகல்

சுருக்கம்

Novel Isozyme-Specific Quantitation Method for Alpha-Amylases in Human Plasma Revealed Possible AMY2B Induction by Alpha-Amylase Inhibitor, CS-1036

Mayumi Hayashi, Toshiyuki Kosaka, Mitsunori Kato, Tomohiro Honda, Takuo Washio, Atsushi Yamasaki, Kazuishi Kubota and Akira Shinagawa

In a clinical trial of an α-amylase inhibitor (CS-1036), which was developed for the treatment of patients with type 2 diabetes, the half-life of plasma CS-1036 concentration was prolonged with the increase of the dose level. The prolonged half-life was assumed to be associated with alternation in the plasma level of any one of the α-amylase isozymes from the treatment. Human α-amylase is classified into 3 isozymes encoded by AMY1A, AMY2A, and AMY2B. Due to high sequence homology between α-amylase isozymes and the low plasma level, it is extremely challenging to quantify individual isozymes. A mass spectrometry-based approach, Multiple Reaction Monitoring (MRM) using the Absolute Quantification (AQUA) strategy, has been applied to quantification of target proteins, and this approach provides high selectivity and specificity. Here we report a novel quantitation method of α-amylase isozymes, which is a combination of purification of α-amylase from plasma by starch affinity adsorption and LCMRM- MS. This method was applied to the plasma samples from the clinical trial of CS-1036. As a result, only AMY2B showed a statistically significant increase in a time-dependent manner. This result suggested that AMY2B might be related to the prolonged half-life of CS-1036.